Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pan-tumor study of ifinatamab deruxtecan in recurrent or metastatic solid tumors
NL-OMON58704Phase 2Recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Feb 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ifinatamab deruxtecan in endometrial cancer (EC), head and neck squamous cell carcinoma (HNSCC), pancreatic adenocarcinoma (PDAC) and 11 more, sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Objective response rate, Dose-limiting toxicities and 1 more. Started Feb 2025; status: recruiting.
02
Drugs
ifinatamab deruxtecan
03
Conditions
endometrial cancer (EC)head and neck squamous cell carcinoma (HNSCC)pancreatic adenocarcinoma (PDAC)colorectal cancer (CRC)hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NL-OMON58704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58704.